Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven

When investigators reviewed Emtricitabine/tenofovir alafenamide in HIV infection, they found that partly no data were available, and partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group, they conclude.

Source: ScienceDaily Headlines - August 18, 2016 Category: Science Source Type: news